Pharma channel feed

Su­per­nus drafts NFL sports­cast­er in me­dia and so­cial blitz for AD­HD med Qel­bree

Last year
Marketing

GSK set­tles an­oth­er heart­burn drug Zan­tac can­cer case in Cal­i­for­nia, does­n't ad­mit li­a­bil­i­ty

Last year
Law

CMS post­pones na­tion­al cov­er­age de­ter­mi­na­tion for PrEP, says de­ci­sion is 'forth­com­ing'

Last year
FDA+

Sanofi and Har­ris Poll glob­al he­mo­phil­ia study finds ‘trou­bling dis­con­nect’ be­tween pa­tients and providers

Last year
Marketing

Mod­er­na's new Covid-19 vac­cine analy­sis 'giv­ing weight' to an­nu­al boost­ing in­ter­val, com­pa­ny says

Last year
Coronavirus

CRO at cen­ter of Pfiz­er’s Ly­me vac­cine study woes says FDA found no tri­al mis­con­duct 

Last year
R&D
FDA+

FDA hits New Jer­sey API man­u­fac­tur­er with 14 de­fi­cien­cies across three sites in Form 483

Last year
FDA+
Manufacturing

Al­most a year since Hu­mi­ra biosim­i­lars launched, Ab­b­Vie still con­trols more than 97% of the US mar­ket

Last year

Em­ploy­ers cov­er­ing GLP-1s could dou­ble in 2024 as ques­tions over cov­er­age guardrails loom

Last year
FDA+

Pfiz­er cuts jobs at Boul­der, CO, re­search fa­cil­i­ty

Last year
People

No­vavax de­buts Covid vac­ci­na­tion cam­paign with celebri­ty spokesper­son as mil­lions of US dos­es ship

Last year
Marketing

Mar­ket­ingRx roundup: Phar­ma brands get cre­ative on In­sta­gram; J&J re­ups health eq­ui­ty chal­lenge

Last year
Marketing

How CVS and Wal­greens are be­com­ing phar­ma’s new big ad­ver­tis­ing strat­e­gy

Last year
Marketing

Flori­da judge dis­miss­es No­vo Nordisk law­suit over com­pound­ed semaglu­tide, but com­pa­ny plans to file again

Last year
Law

Set­ting up a show­down with Boehringer, Pfiz­er scores in­ter­change­abil­i­ty tag for its Hu­mi­ra biosim­i­lar

Last year
FDA+

Astel­las pro­pos­es ‘More Not Flash­es' in first brand­ed ad for Veozah menopause treat­ment

Last year
Marketing

Cal­i­for­nia gov­er­nor ve­toes bill to cap in­sulin prices at $35 per month

Last year
FDA+

Bio­con’s in­sulin biosim­i­lar re­ject­ed yet again by FDA af­ter man­u­fac­tur­ing de­fi­cien­cies

Last year
Manufacturing

Hamas strikes could im­pact some bio­phar­ma op­er­a­tions in Is­rael

Last year
R&D

Scoop: No­var­tis ax­es mid-stage de­pres­sion tri­al of ke­t­a­mine-like in­jec­tion

Last year
R&D

FDA re­jects Al­ny­lam’s On­pat­tro la­bel ex­pan­sion af­ter ad­comm vot­ed in fa­vor

Last year
R&D
FDA+

Gal­der­ma re­news an­nu­al breast can­cer aware­ness cam­paign with per­son­al sto­ries of sur­vivors

Last year
Marketing

CBO analy­sis calls for more re­search in­to sav­ings po­ten­tial for obe­si­ty treat­ments

Last year
FDA+

Pfiz­er and Ab­b­Vie oral mi­graine drugs earn top spots with physi­cians, sur­vey finds

Last year
Marketing
First page Previous page 96979899100101102 Next page Last page
A service from the Financial Times